Breaking News

Financial Report: Bristol-Myers Squibb

January 28, 2016

Opdivo and Hep C franchise sales soar

Bristol-Myers Squibb
4Q Revenues: $4.3 billion (+1%)

4Q Loss: $129 million (earnings were $27 million 4Q14)

FY Revenues: $16.6 billion (+4%)

FY Earnings: $1.7 billion (-17%)

Comments: U.S. revenues increased 9% to $2.3 billion in the quarter. Opdivo sales were $475 million, up from $5 million in 4Q15. Eliquis sales were $602 million compared to $281 in 4Q14. Orencia sales were $540 million, up 22%. Baraclude sales were $309 million in the quarter, down 9% in the quarter. Hepatitis C Franchise sales were $458 million, compared to $207 million in 4Q14. R&D expenses increased 61% to $1.9 billion in the quarter due to higher charges resulting from business development transactions and an in-process research and development (IPRD) impairment.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision